Open Biosystems Launches GIPZ Lentiviral shRNAmir Library
Product News Nov 10, 2006
Open Biosystems, Inc. has announced the availability of its Expression ArrestT GIPZ lentiviral shRNAmir libraries.
Targeting the entire human genome with multiple shRNAmir constructs per gene, the GIPZ lentiviral shRNAmir library builds on Open Biosystems' RNAi technologies that enable researchers to realize the inherent value of RNAi.
The GIPZ library consists of shRNAmir constructs that have been pre-cloned into the GIPZ lentiviral vector, resulting in an RNAi trigger that features increased knockdown specificity and efficiency.
Open Biosystems' GIPZ shRNAmir is designed to provide researchers and scientists with expanded usability and increased delivery into a range of cell types spanning primary and non-dividing cells.
Most recently, the National Cancer Institute (NCI) selected Open Biosystems to verify the effectiveness of shRNAmir technology in 135 specifically targeted cancer genes.
This award will provide researchers with a validated set of cancer gene targeting reagents and data that can be utilized to better identify and study the specific genes involved in the development of cancer.
"Lentiviral shRNAmir is the most powerful RNAi resource available. Open Biosystems continues to arm the research community with the RNAi tools necessary to propel research efforts to the next level," said Troy Moore, chief technology officer at Open Biosystems.
"It remains our mission to provide commercial and academic researchers with the proven tools and technologies to further genomic research that may lead to advanced diagnostics and treatment options for diseases such as cancer, Alzheimer's, diabetes and others."